ADXSW Profile
Advaxis, Inc. (ADXSW) was a biotechnology company that focused on the development of immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 2002 and was headquartered in Princeton, New Jersey. In 2021, the company changed its name to Biosight Therapeutics, Inc. and no longer trades under the ADXSW ticker.
Advaxis was known for its proprietary Lm Technology, which utilized live attenuated Listeria monocytogenes bacteria as a vector to deliver cancer immunotherapies. The company's lead product candidate, ADXS-HPV, was being developed for the treatment of cervical cancer and other HPV-associated cancers. Advaxis was also developing other immunotherapy candidates for the treatment of prostate cancer, bladder cancer, and other types of cancer.
In addition to its cancer immunotherapy pipeline, Advaxis was developing a vaccine candidate for the prevention of Lyme disease, which utilized the same Lm Technology platform. The company had also entered into collaborations with other biotechnology and pharmaceutical companies to develop and commercialize its immunotherapy candidates.
Advaxis was a publicly traded company and was listed on the OTC Pink market. The company's market capitalization and financial performance varied over time, as is typical for early-stage biotechnology companies that are focused on developing novel therapies.
Overall, Advaxis was known for its innovative approach to developing immunotherapies for the treatment of cancer and infectious diseases, and its research and development efforts were seen as a promising development in the fight against these diseases.
|
